首页> 外文期刊>British journal of nursing: BJN >Long-term central IV access in patients with mitochondrial disease.
【24h】

Long-term central IV access in patients with mitochondrial disease.

机译:线粒体疾病患者的长期中枢静脉通路。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mitochondrial disease results from alteration in genes that control mitochondrial function. Patients with this disease present with multisystem organ involvement that may include gastrointestinal (GI) tract dysfunction, including obstruction, pseudo obstruction, bowel infarction and malabsorption syndromes. For this reason, care of this population may require long-term central intravenous (IV) access for administration of hyperalimentation, fluid, medications and blood products. Additionally, these patients may be immunosuppressed and at risk of sepsis. With vulnerability across many organ systems, symptom exacerbation can result from any physiological, psychological, or environmental stressor. There is no cure for mitochondrial disease, and quality-of-life goals are paramount. If GI tract dysfunction develops, treatment may require high-acuity level home care that includes the use of a central IV access device. This article presents an overview of this challenging population, and a plan for safe and effective central IV access care.
机译:线粒体疾病是由控制线粒体功能的基因改变引起的。患有这种疾病的患者存在多系统器官受累,可能包括胃肠道(GI)道功能障碍,包括阻塞,假性阻塞,肠梗塞和吸收不良综合征。由于这个原因,对这个人群的护理可能需要长期中央静脉(IV)通路,以管理饮食,液体,药物和血液制品。另外,这些患者可能被免疫抑制并有败血症的风险。由于跨许多器官系统易受伤害,因此任何生理,心理或环境压力源均可导致症状加重。线粒体疾病无法治愈,生活质量目标至关重要。如果胃肠道功能障碍发展,则治疗可能需要高强度的家庭护理,包括使用中央静脉通路设备。本文概述了这一具有挑战性的人群,并提出了安全有效的中枢IV通路护理计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号